$Telitacicept monotherapy for refractory idiopathic membranous nephropathy: a case report and literature review$

Telitacicept monotherapy for refractory idiopathic membranous nephropathy: a case report and literature review

BackgroundPatients with refractory membranous nephropathy (MN) face risks of progressive renal decline and end-stage renal disease (ESRD), with limited treatment efficacy. Telitacicept, a novel humanized recombinant fusion protein effective in lupus nephritis and immunoglobulin A nephropathy (IgAN),...

Full description

Saved in:

Bibliographic Details
Main Authors:	Shucheng Chen, Yiqi Huang, Zhongjie Qu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-04-01
Series:	Frontiers in Medicine
Subjects:	telitacicept refractory idiopathic membranous nephropathy PLA2R case report literature review
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2025.1571616/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Screening potential diagnostic biomarkers for PLA2R‑associated idiopathic membranous nephropathy by WGCNA analysis and LASSO algorithm
by: Jinxu Huang, et al.
Published: (2025-12-01)

Case Report: A case of membranous nephropathy associated with primary Sjögren’s syndrome treated with telitacicept
by: Juan Chen, et al.
Published: (2025-04-01)

Association of two polymorphisms rs3749117 and rs3749119 in PLA2R1 with idiopathic membranous nephropathy:A Meta-analysis
by: Sheng Qian, et al.
Published: (2021-01-01)

How to Choose Treatment Regimens for Idiopathic Membranous Nephropathy Patients with PLA2R-Negative: A Single-Center Retrospective Cohort Study
by: Zhou Z, et al.
Published: (2025-05-01)

Differences in serum anti-PLA2R antibody determination in Uygur patients with idiopathic membranous nephropathy in Xinjiang
by: ZHANG Jin, et al.
Published: (2018-01-01)

Recurrence of Phospholipase A2 Receptor–Associated Membranous Nephropathy in the Absence of Serum Anti-Phospholipase A2 Receptor Antibodies Reappearance
by: Ilias Bensouna, et al.
Published: (2025-03-01)

Clinical analysis of low-dos erituximab in the treatment of refractory idiopathic membranous nephropathy
by: Yuan Zhong-fei, et al.
Published: (2021-01-01)

Efficacy and safety of telitacicept in IgA nephropathy: a real-world study
by: Lingqiu Dong, et al.
Published: (2025-12-01)

Impact of Time-To-Treatment on Outcomes in Autoimmune Membranous Nephropathy
by: Patrick Hamilton, et al.
Published: (2025-06-01)

Combination Therapy With Rituximab and Low-Dose Cyclophosphamide and Prednisone in Membranous Nephropathy
by: Coralien H. Vink, et al.
Published: (2024-12-01)

Clinical efficacy of tacrolimus combined with glucocorticoids for idiopathic membranous nephropathy
by: LING Yi-sheng, et al.
Published: (2016-01-01)

Obinutuzumab is Effective as an Initial Treatment for PLA2R-Associated Primary Membranous Nephropathy: A Retrospective, Single-Center Trial
by: Li XQ, et al.
Published: (2025-07-01)

Rare coexistence of spinal muscular atrophy with membranous nephropathy – A clinical conundrum with management dilemma
by: Gerry G. Mathew, et al.
Published: (2024-12-01)

A retrospective study of calcineurin inhibitors in the treatment of idiopathic membranous nephropathy
by: CUI Lin-lin, et al.
Published: (2015-01-01)

Research advances of idiopathic membranous nephropathy with non-nephrotic range proteinuria
by: Sun Jing, et al.
Published: (2022-10-01)

Successful treatment of refractory systemic lupus erythematosus-associated immune thrombocytopenia with drug-induced liver injury with telitacicept: a case report and review
by: Xuefei Li, et al.
Published: (2025-03-01)

Clinicopathological analysis of idiopathic membranous nephropathy in different age groups
by: CAI Juan-juan, et al.
Published: (2015-01-01)

Obinutuzumab for treatment of membranous nephropathy in patients positive and negative for the phospholipase A2 receptor antibody: case reports
by: Jinmeng Wang, et al.
Published: (2025-04-01)

A controlled clinical study of efficacy of different treatment regimens for idiopathic membranous nephropathy
by: LUO Man-yu, et al.
Published: (2019-01-01)

Effect of losartan on urinary protein spectrum in patients with idiopathic membranous nephropathy
by: PAN Jing-nian, et al.
Published: (2015-01-01)

Clinical and pathological features of idiopathic membranous nephropathy patients combined with hyperuricemia
by: ZHAO Li, et al.
Published: (2017-01-01)

Clinical observation of responses to two plasma concentrations of tacrolimus in treatment of idiopathic membranous nephropathy stage Ⅱ
by: LI Xiao-yong
Published: (2019-01-01)

Clinical Characteristics and Outcomes of Neural Epidermal Growth Factor-like 1 Protein-Associated Membranous Nephropathy
by: Suruthy Narayanasami, et al.
Published: (2024-05-01)

Correlation of Body Mass Index with Clinicopathologic Parameters in Patients with Idiopathic Membranous Nephropathy [Corrigendum]
by: Chen X, et al.
Published: (2025-08-01)

Association of serum homocysteine levels with acute kidney injury in patients with idiopathic membranous nephropathy
by: XIE Yi-yi, et al.
Published: (2018-01-01)

INVESTIGATION OF THE EFFECT OF PLA2R1 POLYMORPHISM IN PATIENTS WITH MEMBRANOUS NEPHROPATHY
by: Aida Adıkozalova, et al.
Published: (2024-10-01)

Clinical observation of low-dose cyclosporine A combined with small dose of hormone in the treatment of idiopathic membranous nephropathy
by: ZHANG Jian, et al.
Published: (2017-01-01)

Efficacy of tacrolimus or cyclophosphamide combined with glucocorticoids in the treatment of idiopathic membranous nephropathy
by: MAO Wen-li, et al.
Published: (2018-01-01)

Renal tubulointerstitial lesions: a prognostic marker in idiopathic membranous nephropathy
by: Yonghua Liu, et al.
Published: (2025-12-01)

Idiopathic membranous nephropathy with focal segmental sclerosis
by: Elena S. Kamyshova, et al.
Published: (2024-01-01)

The efficacy and safety of ripertamab in the treatment of idiopathic membranous nephropathy: a retrospective multicenter cohort study
by: Xinyang Li, et al.
Published: (2025-07-01)

Correlation analysis of serum IgG with clinicopathological features and prognosis of patients with idiopathic membranous nephropathy
by: LI Xian, et al.
Published: (2025-02-01)

Effect of Telitacicept on Circulating Gd-IgA1 and IgA-Containing Immune Complexes in IgA Nephropathy
by: Jincan Zan, et al.
Published: (2024-04-01)

Clinical characteristics and prognosis of patients with idiopathic membranous nephropathy with kidney tubulointerstitial damage
by: Mengyao Sun, et al.
Published: (2023-12-01)

Acute kidney injury in patients with idiopathic membranous nephropathy: influencing factors and prognosis
by: Zhenzhou Li, et al.
Published: (2023-12-01)

Clinical significance of renal IgM deposition in adult idiopathic membranous nephropathy
by: SUN Yan-jie, et al.
Published: (2018-01-01)

Safety and efficacy of sirolimus combined with cyclosporine in primary membranous nephropathy: a randomized controlled trial
by: Fang Wang, et al.
Published: (2025-05-01)

Anti Phospholipase A2 Receptor 1 Antibodies and Membranous Nephropathy Recurrence After Kidney Transplantation
by: Marion Cremoni, et al.
Published: (2024-12-01)

Analysis of related factors of clinical and renal pathological characteristics in patients with idiopathic membranous nephropathy
by: GUO Guang-feng, et al.
Published: (2020-01-01)

Construction and validation of a predictive model for malignant tumors in patients with membranous nephropathy
by: Yaling Zhai, et al.
Published: (2025-03-01)